Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.74 -2.27 (-2.03%) Market Cap: 6.92 Bil Enterprise Value: 11.03 Bil PE Ratio: 22.63 PB Ratio: 1.87 GF Score: 78/100

Jazz Pharmaceuticals PLC Xywav Investor Update Transcript

Oct 13, 2021 / 08:30PM GMT
Release Date Price: $134.59 (-0.34%)
Operator

Thank you for standing by, and welcome to Xywav in IH launch. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your host, Andrea Flynn, Vice President of Investor Relations. Please go ahead.

Andrea N. Flynn
Jazz Pharmaceuticals plc - VP & Head of IR

Thank you. Good afternoon, everyone, and thank you for joining us today for a discussion on Xywav for idiopathic hypersomnia as we approach our commercial launch. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also reference the press release we issued on August 12 regarding FDA approval of Xywav for the treatment of adults with IH.

On the webcast today are Bruce Cozadd, Chairman and Chief Executive Officer; Dr. Rob Iannone, Executive Vice President, R&D and Chief Medical Officer; and Kim Sablich, Executive Vice President and General Manager, North America.

We're pleased to have external sleep expert, Dr

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot